Abstract 1635P
Background
Assessment of germline BRCA1-2 pathogenic variants (gPV) is routinely recommended in Pancreatic Ductal Adenocarcinoma (PDAC) patients (pts), due to clinical-epidemiological relevance. Limited data are available on the prevalence of gPV in other cancer predisposition genes, including the DNA Damage Response (DDR) system.
Methods
Clinical data of consecutive PDAC pts, of any age and stage, tested with a multigene germline panel between January 2018 and March 2023 in five Italian Institutes were collected. A descriptive analysis of gPV (class 4 and 5) frequency, clinical variables and risk factors, was performed. Since gene panels did not overlap across all Institutes, it was difficult to properly estimate the real prevalence of gPV and to compare the clinical characteristics of all wild type with any-PV population, as screened pts/gene also varied (291-1200). Herein we report the best scenario that may result in rates underestimation.
Results
Among the 1200 pts included in the analysis, 169 (14%) had a gPV (any-PV). 23/73 genes had a gPV in ≥ 1 patient. Genes with a gPV in >1% of tested pts were ATM (36/1200 - 3.0%), BRCA2 (35/1200 - 2.9%), CDKN2A (23/942 - 2.4%), BRCA1 (18/1200 - 1.5%), CHEK2 (11/838 - 1.3%), and COL7A1 (5/447 - 1.1%). Characteristics of the main cohorts are shown in the table. The risk of having a genomic gPV was ≥9% in all the subgroups of pts considered for the different variables, including >73 years old pts (11%). Moreover, 25% of pts with age 41-50, 18% of obese pts and 21% of pts with PDAC/breast/ovarian/prostate cancer/melanoma family history harbored a gPV.
Table: 1635P
Patients’ characteristics [N (%)]
Wild Type1031 | Any Pathogenic Variant169 | BRCA1-2 53 | ATM36 | CDKN2A23 | |
Age | |||||
Median | 66 | 63 | 60 | 63 | 64 |
Range | 28-89 | 26-83 | 44-79 | 38-83 | 51-83 |
≤50 | 84 (8) | 24 (14) | 10 (19) | 5 (14) | 0 |
51-73 | 753 (73) | 122 (72) | 41 (77) | 25 (69) | 18 (78) |
≥74 | 194 (19) | 23 (14) | 2 (4) | 6 (17) | 5 (22) |
Gender | |||||
Female | 525 (51) | 79 (47) | 26 (49) | 14 (39) | 10 (43) |
Stage | |||||
I-II | 256 (27) | 32 (21) | 6 (12) | 12 (38) | 5 (26) |
III | 192 (20) | 31 (20) | 10 (19) | 8 (26) | 2 (11) |
IV | 511 (53) | 92 (59) | 36 (69) | 11 (36) | 12 (63) |
NA | 72 | 14 | 1 | 5 | 4 |
CA19.9 | |||||
Median≤35 | 648191 (22) | 73824 (17) | 9838 (18) | 3882 (6) | 1037 (44) |
>35 | 666 (78) | 113 (83) | 36 (82) | 29 (94) | 9 (56) |
NA | 174 | 32 | 9 | 5 | 7 |
Family history | |||||
Yes | 383 (41) | 103 (65) | 38 (75) | 21 (64) | 15 (79) |
No | 554 (59) | 55 (35) | 13 (25) | 12 (36) | 4 (21) |
NA | 94 | 11 | 2 | 3 | 4 |
NA: not available
Conclusions
Our study highlighted a remarkable prevalence of gPV in cancer predisposition and DDR genes in a large cohort of PDAC pts. These findings endorse the implementation of an extended multigene germline panel to be offered to all PDAC pts, irrespective of age, stage, and personal/family history.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Reni.
Funding
Has not received any funding.
Disclosure
G. Giordano: Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca, Bayer; Financial Interests, Personal and Institutional, Financially compensated role: Servier, Amgen, Seagen, Novartis, Ipsen. M. Reni: Financial Interests, Personal and Institutional, Advisory Board: Eli Lilly, Panavance, Celgene, AstraZeneca, Viatris, Merck Sharp & Dohme, Servier, Sotio, Baxter; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22